Arch Therapeutics, Inc.

FRAMINGHAM, MA · Founded 2009 · Medtech · Defunct

Hemostatic gel that stops bleeding through rapid clot formation

Claim this profile

Follows are private to you and power your alerts

Updated · archtherapeutics.com

Sector
Medtech
Headquarters
FRAMINGHAM, MA
Founded
2009
Latest Form D
$4.2M, Jul 2022
Total capital
$26M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$26M
7 Form D · last Jul 2022
51 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
1 pending

Capital timeline

20132015201720192021FEDERAL ↑EQUITY ↓Cumulative $26M4th Form D$3.4M
20132015201720192021FEDERAL ↑EQUITY ↓Cumulative $26M

Latest events

  • Private capital raisedForm D · SEC · 7th filing$4.2M
  • Private capital raisedForm D · SEC · 6th filing$6.9M
  • Private capital raisedForm D · SEC · 5th filing$550K
  • Private capital raisedForm D · SEC · 4th filing$3.4M
  • Private capital raisedForm D · SEC · 3rd filing$750K
  • Private capital raisedForm D · SEC · 2nd filing$2.9M
  • Private capital raisedForm D · SEC · 1st filing$7.3M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • ALAN W BARBERExecutive OfficerNamed in SEC Form D filings
  • Arthur RosenthalDirectorNamed in SEC Form D filings
  • Avtar W. DhillonDirectorNamed in SEC Form D filings
  • Daniel M. YrigoyenExecutive OfficerNamed in SEC Form D filings
  • Guy W. FishDirectorNamed in SEC Form D filings
  • James W. ShannonDirectorNamed in SEC Form D filings
Show all 16 people
  • James R. SulatDirectorNamed in SEC Form D filings
  • Laurence W. HicksDirectorNamed in SEC Form D filings
  • Michael S. AbramsExecutive OfficerNamed in SEC Form D filings
  • Michael W. BisonExecutive OfficerNamed in SEC Form D filings
  • Norchi TerrenceExecutive Officer, DirectorNamed in SEC Form D filings
  • Punit W. DhillonDirectorNamed in SEC Form D filings
  • Richard E. DavisExecutive OfficerNamed in SEC Form D filings
  • Steven W. KellyExecutive Officer, DirectorNamed in SEC Form D filings
  • Terrence W. NorchiExecutive Officer, DirectorNamed in SEC Form D filings
  • William CotterExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 1
  • PendingCompositions For Prevention Of Adhesions And Other Barrier ApplicationsUSPTOApplication PCTUS2008061622

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .